Directory · KR
Biotechnology Research in South Korea
A register of firms and the professionals working at them in the Biotechnology Research sector based in South Korea. Browse the public index, then filter or export on Kipplo.
Companies
299 on file
Kh Medical
KH Medical is a trailblazing force in the global healthcare landscape, committed to revolutionizing access to high-quality diagnostics for all, particularly in underserved low- and middle-income countries. From its inception, KH Medical has pursued a mission to level the playing field in healthcare, forging powerful alliances with governments, industry leaders, and international organizations worldwide. With a robust portfolio of proprietary technologies, KH Medical stands at the forefront of innovation, uniquely capable of covering both animal and human diagnostics. Our expertise spans the entire spectrum of diagnostic solutions, from raw materials for diagnostic reagents to cutting-edge diagnostic kits, molecular diagnostic extraction equipment, PCR systems, and immunofluorescence devices. KH Medical excels in the development and production of a wide range of high-performance products, including Rapid Tests, FIA Tests, extraction reagents, and PCR reagents, serving both veterinary and human health sectors. Our commitment to excellence is underscored by our ISO 13485 and GMP certifications, which stand as a testament to our relentless focus on quality and continuous improvement. KH Medical is not just a company; it is a beacon of innovation, driven by a vision to ensure that everyone, regardless of their circumstances, has access to the best possible diagnostic tools. By simultaneously advancing human and animal health diagnostics, we are redefining what’s possible in global healthcare.
11 to 50 staff
Kobiolabs Inc
Global Top 10 Player in Microbiome Therapeutics,
51 to 200 staff
Medpacto
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. The leading drug candidate is Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF-β type I receptor (TβRI) currently in phaseⅡ clinical trials with global pharmaceutical companies such as Merck and AstraZeneca. Vactosertib inhibits transforming growth factor-beta (TGF-β) pathway signaling, which is known to promote the metastasis and proliferation of cancer cells by modulating the tumor microenvironment. Vactosertib plays a synergistic role in improving the response to various therapies by inhibiting immune-suppressive TGF-β activity and suppressing the resistance mechanism of cancer stem cells. MedPacto is currently conducting combination trials with Vactosertib targeting several cancer indications including colorectal cancer, pancreatic cancer, sarcomas, NSCLC, bladder cancer, and gastric cancer. Additionally, MedPacto is currently developing MP005A, a new antibody therapeutics targeting BAG2 protein which promotes tumor formation and lung metastasis by binding the enzymes that regulate the tumor microenvironment in cancer development, and MP005D, a diagnostic kit that can detect BAG2 genes.
51 to 200 staff
Naturalendo Tech. Co., Ltd
Naturalendo Tech Co, Ltd. is a bio-tech company certified by the Korean government, specializing in bio-sciences, herbs, and endocrinology. For over a decade, the company has taken traditional oriental medicine and continuously developed its product line. Mission: Naturalendo Tech, world’s best biotech company in natural pharmaceuticals and novel herbal ingredient industry, will contribute for the betterment of human health and wellness based on our technology of endocrinology, gene reporter vector design, herbal medicine screening, and drug delivery. Business lines: Novel Functional Ingredients based on expertised R&D Technology Proprietary Standardized Novel Phytoestrgen: EstroG-100 Human Growth Hormone: IGF-1 Secretaogue Environment Hormone Disruptor DPP-IV Inhibiting Formula: Immune Enhancing Formula: Wellmune New Product Development Trans-dermal Drug Delivery System (TDDS) Anti-atopic dermatitis and Anti-acne Formula: Derma A2 Others
51 to 200 staff
Oscotec Inc
At Oscotec, our mission is to create values by translating cutting edge science into innovative medicines for clinically unmet needs”
51 to 200 staff
Bio Design Lab
We are Bio Design Lab, a South Korean startup developing novel retro- and lentiviral vector platforms that are safer than existing vectors and with high transduction efficiency – the foundation of effective gene, cell, and immunotherapies. With our RetroNext and LentiNext platforms, we are redefining the standards of safety, efficiency, and productivity. Founded in 2018, our mission is to facilitate and accelerate the development of next-generation biopharmaceuticals for currently incurable diseases.
11 to 50 staff
Cj Bio Animal Nutrition & Health
Technologies inspired by nature that gives back to nature. Sustainable life and healthy Earth. This is the philosophy that drives CJ BIO
501 to 1000 staff
Clinomics
The Page for The Leading Company in Precision Medicine for Genome-Based Life, Medical, and Health Care.
51 to 200 staff
Kolon Biotech, Inc
Kolon Biotech provides CDMO services fully engaged in cell & gene therapy that enable successful development of biological therapeutics. Our CDMO service fulfills the established project objectives and works towards the satisfaction of clients. Also, we meet the demands for manufacturing capacity and flexibility by using a manufacturing platform named SACS (Semi-Automated & Closed System) in a cGMP compliant facility. We provide end-to-end CDMO service or each service chosen by clients for what they need (e.g. Process development, Production, QC test, etc.).
51 to 200 staff
Pharmcadd
PharmCADD is a company designed to accelerate drug discovery meanwhile performing a design without building or maintaining the infrastructure associated with high-performance computational resources. The platform for both the design and discovery in the PharmCADD is composed of the state-of-the art technology: AI (Artificial intelligence), Molecular Dynamics (MD), Quantum Calculation (QC), and Network theory. AI, which is data-derived technology emerges as a new trend which could potentially be very revolutionary in our modern world. It enables customers to accelerate the search for a certain or specific drug candidate in the vast existence of chemical space. On the other hand, MD and quantum calculation, physics-based technology, enables the customers to characterize potential drug candidates more precisely. The effective combination of the data-derived and physics-based technologies leads to more accurate and speedier drug discovery.
51 to 200 staff
Aryballe
Aryballe combines biochemistry, advanced optics and machine learning to mimic the human sense of smell. Aryballe’s unique software and data solutions provide odor display and analysis that helps leaders in the automotive, food & beverage, consumer appliance and flavor & fragrance industries make smarter and more informed business decisions. In addition, Aryballe's digital olfaction solutions help companies improve user experiences with applications in the automotive and consumer appliance markets. The company is headquartered in France and with commercial operations in the USA and Korea.
51 to 200 staff
Bbhc-Stri
bBHC Stem Cell Treatment & Research Institute discovered the newly Elicited pluripotent Stem Cell without side effects which is called nEPS. We've been differentiated nEPS into endoderm,mesoderm and ectoderm. Our goal is overcome to incurable diseas using in nEPS.
11 to 50 staff
Cyrus Therapeutics
Cyrus Therapeutics is a leading biotechnology company that is discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs. We are committed to making our mission—‘drugging the undruggable targets’—possible with small molecule drugs as well as new chemical modalities such as targeted protein degraders.
11 to 50 staff
E Green Global
Lab to Farm, a platform tissue culture tech company E Green Global (EGG), an agri-tech company that utilizes plant factory platform, has developed a disruptive technology that overcomes the limitations of the current seed potato supply system and shall lead the global seed potato market as the forerunner. EGG is the ONLY company that has successfully enabled “Lab to Farm” seed potatoes on a global scale. EGG has established the plant factory platform – virus-free Microtubers (bean-sized seed potato) are mass produced in bio-secured lab with environmental control system via in vitro (tissue culturing of plantlets in sterilized vessels), then are directly planted in the open field to produce virus-free high quality seed potatoes in a shorter span of time compared to the conventional method (conventional method requires five years, while EGG’s method requires only one or two) at a competitive price and productivity. “Cheaper, better and more!”
51 to 200 staff
Eutilex
Eutilex is a KOSDAQ listed company that researches and develops new drugs with a focus on immunotherapy
51 to 200 staff
Illimis Therapeutics
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
11 to 50 staff
Inexoplat Inc
Life's moments are precious, and we seize every opportunity to make them count. We pioneer immune-based therapies, setting the standard for transformative cancer treatments, providing hope to patients and striving to improve their quality of life.
1 to 10 staff
L&j Bio Usa, Inc
L&J Bio is committed to developing therapeutic proteins for neurodegenerative diseases through our Dual Action Therapy(DAT) Platform. We have developed innovative therapeutics for Alzheimer's disease through the application of our fusion proteins and implementing DAT to target both amyloid beta and phosphorylated tau proteins. Our mission is to provide safe and effective therapies for patients with serious illnesses. Headquarters and research institute/cGMP facility(future) is located in Maryland, United States, while research institute/office is in Seoul, South Korea. U.S. patent granted in 2024 and IND submission planned for Q1 2026 and Phase I to begin shortly after.
11 to 50 staff
Mxt Biotech
MxT biotech, a Korea University spin-out, is a startup focused on developing transformative microuidic gene delivery platforms for CGT developments.
11 to 50 staff
Panolos Bioscience
Panolos Bioscience is a frontrunner in structure-based protein design and development, with a focus on multi-specific drug development. We specialize in creating anti-angiogenic therapies targeting cancer, autoimmune, and rare diseases. Our proprietary "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific) technology" features a VEGF receptor backbone, enabling the creation of mono- or multi-specific antibody therapeutics with enhanced efficacy. Starting October 2023, PB101 using αART technology is enrolling for Phase I which is manufactured by Samsung Biologics based on a CDMO partnership. Panolos attracted a development partnership with Kelun-Biotech for PB203 (aka, PKB01), and formed the strategic alliance and CDMO partnership with Chime Biologics for the same. Panolos is developing various pipelines targeting PD-L1, EGFR, and TGF-beta(b) To support our ongoing development, Panolos Bioscience raised $18 million in Series A funding and is currently seeking a Series B Bridge investment of $20 million in 2023.
11 to 50 staff
Pin Therapeutics, Inc
Creating Therapeutic Products Degrading Disease-causing Proteins"
11 to 50 staff
Therabest
Therabest is a biopharmaceutical company that develops iPSC-derived immune cells. Our mission is to provide the benefits of cell therapy to many patients. We established a robust process that manufacture Armored iPSC CAR-NK, off-the-shelf cell products using our exclusive technology. Currently, our main pipeline is CD19 (Lymphoid tumor) and Muc1c (Solid tumor). We plan to expand our pipeline through collaboration with companies that own tumor target scFv.
51 to 200 staff
Undbio Pharma Co., Ltd
Inspire a healthier world, and use platform technology skillset to help humanity for a healthy, disease-free world. To be a company that can provide opportunities to achieve and improve the quality of human life
11 to 50 staff
Upstreambio
The Hub of Global Biotechnology, Upstreambio, Inc.
1 to 10 staff
